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Abstract. 
 
Members of the ezrin-radixin-moesin (ERM) 
family of membrane–cytoskeletal linking proteins have 
NH
 
2
 
- and COOH-terminal domains that associate with 
the plasma membrane and the actin cytoskeleton, re-
spectively. To search for ERM binding partners poten-
tially involved in membrane association, tissue lysates 
were subjected to affinity chromatography on the im-
mobilized NH
 
2
 
-terminal domains of ezrin and moesin, 
which comprise the ezrin-radixin-moesin–association 
domain (N-ERMAD). A collection of polypeptides at 
50–53 kD from human placenta and at 58-59 kD from 
bovine brain bound directly to both N-ERMADs. The 
50–53-kD placental proteins migrated as a major 50-kD 
species after phosphatase treatment, indicating that the 
heterogeneity is due to different phosphorylation states. 
We refer to these polypeptides as ERM-binding phos-
phoprotein 50 (EBP50). Sequence analysis of human 
 
EBP50 was used to identify an 
 
z
 
2-kb human cDNA that 
encodes a 357-residue polypeptide. Recombinant 
EBP50 binds tightly to the N-ERMADs of ezrin and 
moesin. Peptide sequences from the brain candidate in-
dicated that it is closely related to EBP50. EBP50 has 
two PSD-95/DlgA/ZO-1–like (PDZ) domains and is 
most likely a homologue of rabbit protein cofactor, 
which is involved in the protein kinase A regulation of 
 
the renal brush border Na
 
1
 
/H
 
1
 
 exchanger. EBP50 is 
widely distributed in tissues, and is particularly enriched 
in those containing polarized epithelia. Immunofluores-
cence microscopy of cultured cells and tissues revealed 
that EBP50 colocalizes with actin and ezrin in the api-
cal microvilli of epithelial cells, and immunoelectron 
microscopy demonstrated that it is specifically 
associated with the microvilli of the placental syncy-
tiotrophoblast. Moreover, EBP50 and ezrin can be coim-
munoprecipitated as a complex from isolated human 
placental microvilli. These findings show that EBP50 is 
a physiologically relevant ezrin binding protein. Since 
PDZ domains are known to mediate associations with 
integral membrane proteins, one mode of membrane 
attachment of ezrin is likely to be mediated through 
EBP50.
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1. 
 
Abbreviations used in this paper
 
: EBP50, ERM-binding-phosphopro-
tein-50; ERM, ezrin-radixin-moesin; ERMAD, ERM-association-domain;
NHE-RF, Na
 
1
 
/H
 
1
 
 exchanger regulatory factor; PDZ, PSD-95/DlgA/ZO-
1–like; PIP
 
2
 
, phosphatidylinositol 4,5-bisphosphate; PKA, cAMP-depen-
dent protein kinase A; PVDF, polyvinylidene fluoride; TKA-1, tyrosine
kinase activator–1.
 
T
 
he 
 
apical aspect of polarized epithelial cells is gen-
erally studded with abundant microvilli containing a
core bundle of actin filaments. To assemble and
maintain the microvilli, the filaments must attach to the
membrane both at the tip of the microvillus, and laterally
down its length (for review see Bretscher, 1991; Mooseker,
1985). Since its discovery, ezrin has been proposed to func-
tion as a membrane–cytoskeletal linking protein that at-
taches the actin filaments laterally to the plasma mem-
brane. This suggestion was based on the finding that ezrin
is a component of the isolated intestinal microvillus cy-
toskeleton and is specifically enriched in actin-containing
surface structures on cultured cells (Bretscher, 1983).
Ezrin is one member of a family of closely related pro-
teins known as the ezrin-radixin-moesin (ERM)
 
1
 
 family
(Gould et al., 1989; Turunen et al., 1989; Funayama et al.,
1991; Lankes and Furthmayr, 1991; Sato et al., 1992).
These proteins all possess a 
 
z
 
300-residue NH
 
2
 
-terminal
domain that shares sequence homology with the corre-
sponding domain of erythrocyte band 4.1, followed by an
 
z
 
170-residue region predicted to be largely 
 
a
 
-helical, and
terminating in a 
 
z
 
100-residue domain in which an F-actin
binding site resides (Turunen et al., 1994; Pestonjamasp et
al., 1995; Yao et al., 1996). Further support for a mem-
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brane–cytoskeletal linking role came from the knowledge
that the NH
 
2
 
-terminal domain of band 4.1 binds to the
membrane protein glycophorin C in an association en-
hanced by an additional factor known as p55 (Marfatia et
al., 1994, 1995).
Various laboratories have tried to identify ERM-bind-
ing proteins by using coimmunoprecipitation approaches.
Using an antibody to moesin, Tsukita et al. (1994) re-
ported that the hyaluronate receptor CD44 binds to the
ERM proteins. Recently, they have shown that CD44 as-
sociates with the NH
 
2
 
-terminal domains of all family mem-
bers in a PIP
 
2
 
-dependent manner (Hirao et al., 1996). Us-
ing a similar immunoprecipitation approach, we discovered
that ezrin associates with a subpopulation of moesin in cul-
tured cells where both are expressed. This result led to the
finding that ezrin and moesin can form very tight homo- or
heterotypic associations when expressed in the same cell
(Gary and Bretscher, 1993).
The discovery that ezrin associates either with itself or
with moesin gave rise to a paradox because the bulk of sol-
uble ezrin in tissue homogenates exists in monomeric form
(Bretscher, 1983, 1989). To help resolve this issue, ezrin’s
self-association domains were delineated, and their acces-
sibility in isolated monomers was determined (Gary and
Bretscher, 1995). This study revealed that ezrin contains
an NH
 
2
 
-terminal domain of 
 
z
 
300 residues that can bind
with high affinity to a 
 
z
 
100-residue COOH-terminal do-
main. Because the NH
 
2
 
-terminal domain can associate
with the COOH-terminal domain of any ERM member,
the domains were termed N- and C-ERMADs (ERM-
association domain). The N-ERMAD coincides with the
band 4.1 homology domain, a region of the molecule
folded into a compact structure based on its relative resis-
tance to protease (Franck et al., 1993). The C-ERMAD
follows the region predicted to be largely 
 
a
 
-helical, and is
also relatively protease resistant (Gary and Bretscher, 1995;
Niggli et al., 1995). Using bacterially expressed N-ERMAD
as a probe, it was found that the activity of the C-ERMAD
is masked in the native monomer, thus explaining why
ezrin can exist as a monomeric protein in the cytoplasm.
Moreover, the C-ERMAD contains the F-actin binding
site, which is also expected to be masked in the isolated
monomer (Gary and Bretscher, 1995). When the C-ERMAD
is exposed by unfolding agents, it readily binds to an
N-ERMAD. Although these results were most exhaus-
tively shown for ezrin and to a lesser degree for moesin
(Gary and Bretscher, 1995), the model likely extends to
radixin. Indeed, Magendantz et al. (1995) showed that im-
mobilized radixin N-ERMAD will bind full-length, dena-
tured radixin where the radixin C-ERMAD is expected to
be exposed. Also consistent with the concept that the
C-ERMAD has activities normally masked in the intact
molecule, is the finding that high level expression of this
domain, but not the intact molecule or NH
 
2
 
-terminal do-
main, causes the formation of long appendages on trans-
fected cells (Henry et al., 1995; Martin et al., 1995).
Based on these studies, and the finding that isolated mi-
crovilli contain a preponderance of ezrin oligomers over
monomers, we proposed that ezrin can exist in vivo in both
dormant and activated states (Berryman et al., 1995; Gary
and Bretscher, 1995). Activation of the monomer, perhaps
by phosphorylation, induces a conformational change that
exposes the masked C-ERMAD, thereby allowing self-
association. In addition, activation may lead to the expo-
sure of the COOH-terminal F-actin binding site, and pos-
sibly of a masked membrane association site (Berryman et
al., 1995). Since the membrane association site might be
masked in the dormant monomer, we sought to identify
proteins that would bind to the isolated N-ERMAD.
In this study, we describe a protein that binds to the
N-ERMADs of ezrin and moesin. The isolation, identifi-
cation, and colocalization of this protein with ezrin in cell
surface structures is reported here.
 
Materials and Methods
 
Materials
 
Human placenta was obtained from consenting patients at Tompkins
Community Hospital (Ithaca, NY). Bovine brain was provided by Dr. W.
Brown (Cornell University, Ithaca, NY). Adult female CD-1 mice were
provided by Dr. M. Salpeter and M. Strang (Cornell University). Restric-
tion enzymes and other reagents for molecular biology were purchased
from GIBCO BRL (Gaithersburg, MD).
 
Production and Purification of Recombinant Proteins
 
The cDNA sequences encoding the human ezrin and moesin N-ERMADs
(amino acids 1–296) were amplified by PCR from clones F6 (Gould et al.,
1989) and HEBA06 (a gift from Dr. Stachowitz, Gezentrum, Munich,
Germany), respectively, using primers which generated EcoRI and Hind-
III sites at their ends. These products were then subcloned into the ex-
pression vector pQE16 (QIAGEN Inc., Chatsworth, CA). The cDNA se-
quence encoding residues 1-357 of ERM-binding phosphoprotein 50
(EBP50) was amplified by PCR with SphI and HindIII sites at the ends
and subcloned into pQE70 (QIAGEN Inc.). Vector sequences coding for
the six histidine tags were absent in all of the final constructs. To make the
EBP50 COOH-terminal construct, the cDNA sequence encoding residues
241–357 was amplified by PCR using primers that created HindIII and
BglII sites at the ends. This product was joined with the 0.99-kb BglI/Hind-
III fragment of pQE50 (QIAGEN Inc.) and the 2.42-kb BglI/BglII frag-
ment of pQE16 in a three-arm ligation reaction to create the final His-
tagged fusion construct. All recombinant sequences were determined to
be free of PCR errors by nucleotide sequence analysis. Recombinant plas-
mids were propagated in the JM109 strain of 
 
Escherichia coli
 
 (Stratagene,
La Jolla, CA).
For protein expression, plasmid constructs were transformed into the
 
E. coli
 
 strain M15[pRep4] (QIAGEN, Inc.). Saturated overnight cultures
were inoculated at 1:20 dilution in LB medium containing 100 
 
m
 
g/ml
ampicillin and 25 
 
m
 
g/ml kanamycin, and grown for 90 min at 37
 
8
 
C. Isopro-
pyl 
 
b
 
-
 
d
 
-thiogalactopyranoside was added to 2 mM and cells were grown
for an additional 180 min. Cells were harvested by centrifugation at 8,000 
 
g
 
for 15 min. Total bacterial lysates were prepared from cells resuspended
in 1 vol of Laemmli buffer (Laemmli, 1970), boiled 2 min, and then passed
through a 28-gauge needle to reduce viscosity.
To purify bacterially expressed ezrin or moesin N-ERMAD, induced
cells were resuspended in 6 vol of 180 mM KH
 
2
 
PO
 
4
 
, pH 7.0, at 4
 
8
 
C, con-
taining 50 
 
m
 
g/ml PMSF and 75 
 
m
 
g/ml benzamidine, lysed by sonication
(Branson Ultrasonics Corp., Danbury, CT), clarified at 45,000 
 
g
 
 for 10
min, and then loaded onto a preequilibrated hydroxyapatite column
(HA–Ultragel; Pharmacia Fine Chemicals, Piscataway, NJ). The column
was developed using a six-column volume linear gradient of 180–800 mM
KH
 
2
 
PO
 
4
 
, and fractions were monitored by SDS-PAGE on 15% gels. Frac-
tions rich in N-ERMAD were pooled, dialyzed against 20 mM MES, 150
mM NaCl, pH 6.7, at 4
 
8
 
C, centrifuged at 45,000 
 
g
 
 for 10 min, applied to a
preequilibrated S-Sepharose column (Pharmacia Fine Chemicals, Piscat-
away, NJ), and developed with a five-column volume linear gradient of
0.15–1.0 M NaCl. Homogenous N-ERMAD eluted at 
 
z
 
490 mM NaCl.
To purify recombinant EBP50, induced bacterial lysates were prepared
in TBS (50 mM Tris, 0.15 M NaCl, pH 7.4, at 4
 
8
 
C) in the presence of pro-
tease inhibitors, according to the method described above, and EBP50 af-
finity purified using N-ERMAD–coupled beads in a manner analogous to
that used in the affinity binding assay. After washing the beads in TBS 
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made up to 0.5 M NaCl, bound EBP50 was eluted with 2 M NaI, or by
boiling the beads in Laemmli buffer.
The His-tagged EBP50 COOH-terminal fusion product was purified on
nickel nitrilo-triacetic acid resin (QIAGEN) under denaturing conditions
in 8 M urea, according to the manufacturer’s protocol.
 
Affinity Binding Assay
 
Purified N-ERMAD proteins and BSA were coupled covalently to CNBr-
activated Sepharose 4B (Sigma Chemical Co., St. Louis, MO) at a final
concentration of 2 mg/ml. Specifically, dried beads were swelled for 15
min in 1 mM HCl at room temperature, and then washed once in ice-cold
C buffer (0.1 M NaHCO
 
3
 
, 0.5 M NaCl, pH 8.3, at 4
 
8
 
C). Purified protein in
C buffer was immediately added to these beads and incubated for 16 h at
4
 
8
 
C with gentle inversion. The beads were pelleted at 3,000 
 
g
 
 for 10 s, the
supernatant removed, and the remaining active groups on the beads
blocked by a 16-h incubation in 0.25 M glycine, pH 8.0, at 4
 
8
 
C. Beads were
washed five times in C buffer, and finally stored for use as a 25% slurry at
4
 
8
 
C in H buffer (50 mM Tris, 0.15 M NaCl, 1% Triton X-100, pH 7.4, at
4
 
8
 
C) made 0.2% with NaN
 
3
 
. For each set of beads made, samples of the
starting protein solution and the post-couple supernatant were compared
by SDS-PAGE to determine the efficiency of the coupling reaction, which
in all cases for the beads used was 
 
.
 
95%.
Lysates were prepared from tissues that had been stored frozen at
 
2
 
80
 
8
 
C. Tissues were thawed at 4
 
8
 
C, and homogenized in a blender (War-
ing Products Div., New Hartford, CT) in 2 ml H buffer per gram (wet
weight) of tissue in the presence of 50 
 
m
 
g/ml PMSF and 75 
 
m
 
g/ml benzami-
dine. Homogenates were clarified by centrifugation at 48,000 
 
g
 
 for 15 min
at 4
 
8
 
C, and the resulting supernatant was then recentrifuged at 200,000 
 
g
 
for 30 min at 4
 
8
 
C to yield a soluble lysate with a protein concentration of
 
z
 
5 mg/ml.
Affinity binding assays were carried out by mixing 50 
 
m
 
l of a 25% slurry
of coupled beads with 1 ml of tissue lysate at 4
 
8
 
C for 2 h. For some reac-
tions, a fourfold excess (100 
 
m
 
g) of soluble ezrin N-ERMAD or BSA was
also included. The beads were washed six times in 1 ml H buffer made up
to 0.5 M NaCl, and bound lysate proteins extracted by boiling for 2 min in
Laemmli buffer.
For the large-scale affinity precipitation of EBP50 from tissues, the af-
finity bead-binding assay was scaled up 
 
z
 
100-fold. Beads that had been
incubated with lysate were transferred to a 5-ml chromatography column,
and washed with five column volumes of H buffer. Bound protein was col-
lected in 0.3-ml fractions while eluting with two column volumes of 8 M
urea buffered with 50 mM Tris, pH 7.4, at 4
 
8
 
C.
 
Phosphatase Assays
 
Human placental EBP50 was affinity purified on N-ERMAD beads, col-
lected by elution in 2 M NaI, and then dialyzed against 50 mM Hepes, 1
mM MgCl
 
2
 
, pH 7.5, at 4
 
8
 
C. Treatments with calf intestine alkaline phos-
phatase (Sigma Chemical Co.) were performed essentially according to
the method described by Coligan et al. (1996). Reactions were set up using
 
z
 
3 
 
m
 
g EBP50 and 0.6 U phosphatase, incubated for 15 min at 30
 
8
 
C, and
then terminated by boiling in Laemmli buffer. In control reactions, EBP50
was incubated either in buffer alone or in the presence of the phosphatase
and the inhibitors 10 mM 
 
b
 
-glycerophosphate and 100 
 
m
 
M Na
 
3
 
VO
 
4
 
.
 
Antibodies
 
Antibodies to EBP50 were raised in rabbits and affinity purified as de-
scribed (Bretscher, 1983) using purified recombinant human EBP50
COOH terminus as antigen. Affinity-purified antibodies to human placen-
tal ezrin have been described (Bretscher, 1989; Franck et al., 1993).
 
SDS-PAGE, Blot Overlays, and Immunoblots
 
SDS-PAGE was performed according to Laemmli (1970). Gels were
stained with Coomassie brilliant blue R-250, or were silver stained (Oak-
ley et al., 1980). For blots, proteins were transferred from gels to polyvi-
nylidene fluoride (PVDF) membranes (Millipore Corp., Bedford, MA)
using a semidry electroblotter (Integrated Separation Systems, Hyde
Park, MA). All blots were developed using an enhanced chemilumines-
cence detection system (Amersham Corp., Arlington Heights, IL).
Biotinylated N-ERMAD and EBP50 probes were prepared and blot
overlays were performed as described (Gary and Bretscher, 1993). The bi-
otinyl probes were omitted in control experiments. Purified human pla-
cental ezrin and moesin were prepared as described (Bretscher, 1989).
Immunoblots were blocked with 10% nonfat dry milk, then probed
with 0.1 
 
m
 
g/ml affinity-purified EBP50 or ezrin antibodies in 1% milk, fol-
lowed by 0.1 
 
m
 
g/ml peroxidase-conjugated goat anti–rabbit IgG in 1%
milk. Primary antibodies were omitted for control blots.
Murine tissue samples were obtained from adult female CD-1 mice.
Total SDS-soluble lysates were prepared from fresh tissues or cells ho-
mogenized in Laemmli buffer, boiled 2 min, sonicated 15–30 s, and centri-
fuged 100,000 
 
g
 
 for 30 min at 20
 
8
 
C. The resulting supernatants were col-
lected for analysis. Human placental microvilli were prepared as described
(Berryman et al., 1995) and total SDS-soluble lysates made as above.
 
Sequence Analysis
 
EBP50 was affinity purified from human placenta or bovine brain using
N-ERMAD beads in the large-scale, affinity binding assay. Approxi-
mately 8 
 
m
 
g of each protein was resolved by preparative SDS-PAGE, and
then blotted to PVDF. The membrane was stained with Ponceau-S (Sigma
Chemical Co.) and regions containing the desired EBP50 bands were ex-
cised and then washed extensively in double-distilled water. Amino acid
analysis and peptide microsequencing was performed at Harvard Micro-
chem (Cambridge, MA). Samples were digested in situ with endoprotein-
ase lys-C, subjected to HPLC fractionation, and the peak fractions were
analyzed using matrix-assisted laser desorption time-of-flight mass spec-
trometry. Homogenous fractions were then chosen for automated peptide
sequencing. Peptide sequences (see Figs. 4 and 5) were used to query the
National Center for Biotechnology Information (Bethesda, MD) nonre-
dundant database using the BLAST program (Altschul et al., 1990).
The Institute for Genomic Research (Rockville, MD) human cDNA
database was searched using the EBP50 peptide sequences. cDNA clones
that matched these query sequences were obtained from Genome Systems
Inc. (St. Louis, MO). The insert sizes were determined by restriction en-
donuclease digestion using enzymes appropriate for the cloning sites in
each library parent vector. The cDNA insert of a clone from a human in-
fant brain library was sequenced in its entirety using a set of four oligonu-
cleotide primers that yielded overlapping sequence information. All nu-
cleotide sequencing was done using an automated cycle sequencer (model
373A; Applied Biosystems, Inc., Foster City, CA).
The software programs, EDITSEQ and MEGALIGN (DNASTAR
Inc., Madison, WI), were used for DNA and protein sequence editing, and
protein sequence alignments, respectively.
 
Immunofluorescence and Immunoelectron Microscopy
 
Cryosections of human placenta were prepared and stained as described
(Berryman et al., 1993). Murine intestinal epithelial cells were prepared
and stained as described (Bretscher and Weber, 1978). Affinity-purified
EBP50 antibodies were used at 3 to 5 
 
m
 
g/ml. Tissue sections were viewed
using a Zeiss Axioskop fluorescence microscope (Carl Zeiss Inc., Thorn-
wood, NY) and images were recorded on Kodak T-Max 400 film (East-
man Kodak Co., Rochester, NY).
JEG-3 cells obtained from the American Type Culture Collection
(Rockville, MD) were grown on glass coverslips in MEM supplemented
with 10% FCS and stained for microscopy as described in Franck et al.
(1993), using 3 
 
m
 
g/ml of affinity-purified EBP50 antibodies. Cells were
viewed with a Zeiss Axiovert 100-TV fluorescence microscope (Carl Zeiss
Inc.), and images were acquired using Metamorph imaging software (Uni-
versal Imaging Corp., West Chester, PA).
Immunoelectron microscopy was performed as described (Berryman et
al., 1993).
 
Immunoprecipitation
 
Human placental microvilli were prepared, and radioimmunoprecipita-
tion assay (RIPA) extracts were made as described (Berryman et al.,
1995). Ezrin and EBP50 were immunoprecipitated from 300 
 
m
 
l of soluble
extract of microvilli using 7 
 
m
 
l of antiserum and 25 
 
m
 
l of protein A–Sepharose
beads (Sigma Chemical Co.). In some experiments, 50 
 
m
 
g of purified hu-
man ezrin was included in the reaction mixture as competitor. Immuno-
precipitates were washed with RIPA buffer and eluted by boiling in
Laemmli sample buffer. The immunoprecipitates were run on SDS-
PAGE, blotted to PVDF, and probed with biotinylated EBP50 or ezrin
antibodies. Avidin peroxidase (ExtrAvidin; Sigma Chemical Co.) was
used as a secondary detection reagent. 
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Results
 
Identification of Ezrin and Moesin
N-ERMAD Binding Proteins
 
The N-ERMADs of human ezrin and moesin (residues
1–296) were expressed as soluble, untagged proteins in
bacteria, and purified to homogeneity (Fig. 1, 
 
A
 
 and 
 
B
 
).
Because N-ERMADs require a native conformation for
their activity in a blot overlay assay (Gary and Bretscher,
1995), we tested the ability of these bacterially expressed
products to bind purified ezrin and moesin. Both recombi-
nant ERMADs bound specifically to human placental ezrin
and moesin that had been electrophoresed and blotted to
a membrane (Fig. 1 
 
C
 
). These results suggested that they
were native in conformation and therefore suitable for use
in the search for binding proteins.
An affinity binding assay was used in which the native
N-ERMADs were immobilized on agarose beads, mixed
with detergent-soluble tissue lysates, washed extensively,
and then any binding proteins were eluted by boiling in
SDS. A set of beads to which an identical amount of BSA
was coupled served as a control. Using this assay, lysates
of human placenta were found to contain a group of
polypeptides of apparent molecular mass 50–53 kD that
bound specifically to the ezrin and moesin N-ERMAD
beads (Fig. 2 
 
A
 
, lanes 
 
5
 
 and 
 
6
 
), but not to the control beads
(Fig. 2 
 
A
 
, lane 
 
4
 
). Similarly, lysates of bovine brain con-
tained polypeptides of apparent molecular mass 58–59 kD
that bound specifically to both sets of N-ERMAD beads
(Fig. 2 
 
A
 
, lanes 
 
10
 
 and 
 
11
 
). The presence of a small
amount of ezrin, as confirmed by immunoblot analysis
(data not shown), was also seen in both of the N-ERMAD
eluates from placenta (Fig. 2 
 
A
 
, lanes 
 
5
 
 and 
 
6
 
). This ezrin
was probably recovered due to association between the
immobilized N-ERMAD and a small amount of soluble ezrin
having an exposed C-ERMAD, or by virtue of being bound,
either directly or indirectly, to the placental N-ERMAD–
binding candidates.
The specificity of binding between the N-ERMADs and
the placental and brain candidates was examined further.
The ability of the moesin N-ERMAD beads to bind these
proteins from lysates containing a fourfold excess of un-
coupled ezrin N-ERMAD was tested. Under these condi-
tions, the entire series of placental and brain candidate
bands, as well as the small amount of ezrin precipitated
from placenta, was specifically competed away (Fig. 2 
 
A
 
,
lanes 
 
7
 
 and 
 
12
 
). In mock competitions where a fourfold ex-
cess of uncoupled BSA was used, the recovery of the can-
didate proteins and ezrin was unaffected (Fig. 2 
 
A
 
, lanes 
 
8
 
and 
 
13
 
). These results indicate that the presence of the
N-ERMAD in solution can prevent the binding of the
candidates and ezrin to the beads. Since the soluble ezrin
N-ERMAD diminished the binding of the candidates to the
moesin N-ERMAD beads, it is likely that the candidates
associate with homologous sites on the ezrin and moesin
N-ERMADs.
To determine if the interaction between the candidates
and the N-ERMAD might be direct, biotinylated ezrin
N-ERMAD was used as a probe in a blot overlay assay on
the samples shown in Fig. 2 
 
A.
 
 Fig. 2 
 
B
 
 shows that the bi-
otinylated N-ERMAD bound not only to the 50–53-kD
placental polypeptides (Fig. 2 
 
B
 
, lanes 
 
5
 
, 
 
6
 
, and 8) but also
to the 58–59-kD brain polypeptides (Fig. 2 B, lanes 10, 11,
and 13). The candidate proteins were also detected in sam-
ples of the starting lysates (data not shown). The ezrin in
the placental precipitates was specifically recognized on
the blot because of the association between its exposed
C-ERMAD and the N-ERMAD probe (Fig. 2 B, lanes 5,
6, and 8). In those instances where soluble ezrin N-ERMAD
competitor was used in the binding assay, neither the can-
didates nor ezrin was detected, corroborating the specific-
ity of the affinity binding assay (Fig. 2 B, lanes 7 and 12).
These results demonstrate a direct association between
the placental and brain candidates and the N-ERMADs of
ezrin and moesin.
Figure 1. Purification and characterization of ezrin and moesin
N-ERMADs. (A and B) show the purifications. Samples were
run on a 15% SDS gel and stained with Coomassie blue. Lane 1,
total extract of uninduced bacteria; lane 2, total extract of in-
duced bacteria; lane 3, purified proteins. (C) The recombinant
proteins exhibit ERMAD activity. Blot overlays using biotinyl
ezrin N-ERMAD (E-N) and biotinyl moesin N-ERMAD (M-N)
probes on a mixture of ezrin and moesin are shown. The mobili-
ties of molecular mass standards and of placental ezrin (81) and
moesin (77) are indicated in kD. DF, dye front.Reczek et al. EBP50, an Ezrin-Radixin-Moesin–binding Protein 173
Sequence Analysis of the Binding Candidates Reveals 
Homologous Proteins with PDZ Domains
A scaled-up version of the affinity binding assay was used
to acquire sufficient amounts of each candidate for se-
quence analysis. The placental 50–53-kD bands were sig-
nificantly enriched in the peak fractions (Fig. 3 A). Under
these conditions, three major placental polypeptide bands,
which we designate a, b, and g, were resolved (Fig. 3 B).
Amino acid analysis of each of these bands indicated es-
sentially identical compositions, suggesting that they might
be posttranslationally modified species of the same poly-
peptide. Although antiphosphotyrosine immunoblots indi-
cated that the heterogeneity was apparently not the result
of tyrosine phosphorylation (data not shown), treatment
of the placental candidates with calf intestinal alkaline
phosphatase resulted in a collapse of most or all of these
species into a major polypeptide band migrating at 50 kD
(Fig. 3 C, lane 2). Control experiments in which the en-
zyme was omitted, or phosphatase inhibitors were in-
cluded, showed no detectable change in the migration of
p50 a, b, or g (Fig. 3 C, lanes 1 and 3). Therefore, most or
all of the heterogeneity of the placental species is due to
varying degrees of serine and/or threonine phosphoryla-
tion of a 50-kD polypeptide. We refer to this collection of
polypeptides as EBP50.
Two peptide sequences were derived from g-EBP50,
KGPNGYGFHLHGEK, and KRAPQMDWSK. Database
searches revealed that closely related sequences are
present in rabbit protein cofactor (Weinman et al., 1995)
and that a sequence related to the first peptide is present
in human tyrosine kinase activator–1 (TKA-1) (these se-
quence data are available from EMBL/GenBank/DDBJ
under the accession number Z50150). Protein cofactor,
also known as NHE-RF (Na1/H1 exchanger regulatory
factor) is a 358-residue protein that is involved in the
cAMP-dependent protein kinase A (PKA) regulation of
the rabbit renal brush border Na1/H1 ion exchanger
(Weinman et al., 1995; Yun et al., 1997). Information sub-
mitted to GenBank (K. Seedorf and A. Ullrich, April
1996) indicates that TKA-1 may be a novel cellular ty-
rosine kinase–binding protein that activates the signaling
potential of the PDGF receptor. In addition, Yun et al.
(1997) recently showed that TKA-1, renamed E3KARP,
Figure 2. Identification of N-ERMAD binding proteins. (A) Ly-
sis buffer, or placental extracts, or brain extracts were mixed with
BSA–agarose (BSA), ezrin–N-ERMAD-agarose (E-N), or moesin–
N-ERMAD-agarose (M-N), and then were washed extensively in
0.5 M NaCl and bound proteins eluted and resolved on a 6–20%
silver stained gradient SDS gel. For some reactions, a fourfold
molar excess of competitor ezrin N-ERMAD (1 C) or mock
competitor BSA (1 mock) was added to the extract before mix-
ing with moesin–N-ERMAD-agarose. (B) One quarter the
amount of the same samples shown in A were resolved on a 10%
gel, transferred to PVDF, and probed with biotinylated ezrin–
N-ERMAD. Brackets indicate the N-ERMAD binding proteins,
and arrowheads indicate ezrin. The mobilities of standard pro-
teins are indicated in kD. DF, dye front.
Figure 3. Isolation and char-
acterization of the human
placental N-ERMAD bind-
ing candidates. (A) An affin-
ity binding assay similar to
that shown in Fig. 2, was
scaled up 100-fold, and
bound proteins were eluted
with urea. A silver-stained
12% gel of the peak fractions
is shown; the region in which
the binding proteins migrate
is bracketed. (B) Enlarged
view to show resolution of
the placental candidates into
three species: a, b, and g. (C)
Binding protein heterogene-
ity is due to phosphorylation.
The proteins were recovered
from ezrin–N-ERMAD aga-
rose beads by elution with NaI,
treated with alkaline phos-
phatase, and then analyzed on a 10% gel. Lane 1, untreated sample;
lane 2, phosphatase-treated sample; lane 3, phosphatase-treated
sample in the presence of phosphatase inhibitors. The arrow indi-
cates the migration position of alkaline phosphatase. DF, dye
front.The Journal of Cell Biology, Volume 139, 1997 174
binds to the NHE3 Na1/H1 exchanger and subjects it to
PKA regulation.
The human expressed sequence tag (EST) database was
found to contain a cDNA clone encoding the EBP50 pep-
tide sequences. The 2.0-kb insert contained an open read-
ing frame of 357 residues, with a predicted molecular mass
of 38.6 kD (Fig. 4). An alignment of the EBP50 protein se-
quence with that of rabbit protein cofactor and TKA-1 is
shown in Fig. 5. EBP50 exhibits 84 and 48% overall se-
quence identity to rabbit protein cofactor and TKA-1, re-
spectively. In contrast to EBP50 and protein cofactor,
which align very well over their entire lengths, the se-
quence of TKA-1 diverges after G261 in EBP50. These
findings suggested that the correct cDNA had been ob-
tained using the placental candidate peptide sequences,
and that human EBP50 might be a homologue of rabbit
protein cofactor, and a relative of human TKA-1.
Inspection of the deduced EBP50 protein sequence re-
vealed the presence of two z90-residue repeats in the
NH2-terminal half of the molecule between L11-E97 and
L149-E236. These repeats, which share 74% sequence
identity, are also found in nearly identical versions in both
protein cofactor and TKA-1 (Fig. 5). Database searches
using the isolated sequences from each EBP50 repeat
yielded, in addition to the expected matches with protein
cofactor and TKA-1, a list of more distantly related pro-
teins including: the tumor suppressor product of the
Drosophila discs large gene; the synapse-associated pro-
teins PSD-95/SAP90, chapsyn 110, SAP97, and SAP102;
the human tyrosine phosphatase PTPL1; the Drosophila
InaD protein; and the human tight junction protein zonula
occludin–1, among others. The common feature among
these proteins is the presence of one or more PDZ do-
mains (Fig. 6). Thus, EBP50, rabbit cofactor, and TKA-1
all have two closely related PDZ domains followed by a
120–220-residue COOH-terminal tail.
Sequence analysis of peptides derived from the 59-kD
bovine brain N-ERMAD binding candidate yielded three
sequences (KVGQYIRLVEPGSPAEK, KETHQQVVN-
RIRA, and KLLVVDRETDEFFK) that are almost iden-
tical to sequences in the PDZ containing regions of EBP50
(Fig. 5). Therefore, the brain candidate is probably the bo-
vine homologue of EBP50 or a very closely related protein.
Expression and Purification of Recombinant EBP50
Recombinant full-length EBP50 was generated to allow
for additional characterization of its interaction with the
N-ERMADs. Although the protein was expressed poorly
in E. coli, soluble EBP50 could be purified to homogeneity
by affinity chromatography on either ezrin N-ERMAD or
moesin N-ERMAD beads (Fig. 7 A). The expressed pro-
tein, predicted to have a mass of 38.6 kD, migrated anoma-
Figure 4. Nucleotide and derived protein sequence of human
EBP50 cDNA. Residues matching the two placental g-EBP50 pep-
tide sequences are underlined. These sequence data are available
from EMBL/GenBank/DDBJ under accession number AF015926.
Figure 5. Human EBP50 has homology to rabbit protein cofactor
and human TKA-1. Identities are boxed. Sequences correspond-
ing to the z90-residue PDZ domains in each of these proteins are
underlined with thick lines. The locations of sequences of the
three peptides derived from the bovine N-ERMAD binding pro-
tein are indicated by thin lines. The protein cofactor and TKA-1
sequence data are available from EMBL/GenBank/DDBJ under
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lously by SDS-PAGE with an apparent mass of 50 kD,
which is the same mobility seen for placental EBP50 after
phosphatase treatment (Fig. 7 B). The similar mobilities of
the bacterially expressed open reading frame and the de-
Figure 6. Alignment of the two PDZ domains of
human EBP50, rabbit cofactor and human TKA-1
with PDZ domains of selected other proteins:
Drosophila Dlg-A (these sequence data are
available from EMBL/GenBank/DDBJ under
accession number M73529), human chapsyn-110
(accession number U32376), murine PSD-95 (ac-
cession number D50621), and human PTPL1 (ac-
cession number X80289). The domains have been aligned to optimize the conserved residues, shown in bold, as proposed by Ponting
and Phillips (1995). A more complete alignment of other PDZ domains by Ponting and Phillips can be found at: http://biop.ox.ac.uk/
www/dhr.html
Figure 7. Expression, purification, and characterization of re-
combinant EBP50. (A) Expression and purification of EBP50.
Samples were run on an 11.5% SDS gel and stained with Coo-
massie blue. Lane 1, total extract of uninduced bacteria; lane 2,
total extract of induced bacteria; lane 3, EBP50 purified on im-
mobilized ezrin N-ERMAD; lane 4, EBP50 purified on immobi-
lized moesin N-ERMAD. (B) Recombinant EBP50 comigrates
with phosphatase-treated EBP50 (1AP) and migrates faster than
untreated EBP50 (2AP). The latter two lanes are the same as
those shown in Fig. 3 C. (C) Biotinylated ezrin N-ERMAD (E-N)
or moesin N-ERMAD (M-N) binds to recombinant EBP50 by
blot overlay. (D) Biotinylated recombinant EBP50 binds to ezrin
and moesin N-ERMADs by blot overlay. Samples in panels C
and D were resolved on 10 and 15% SDS gels, respectively, and blot-
ted as in Fig. 2. The migration positions of the isolated N-ERMADs
(35 kD) and of EBP50 (50 kD) are shown. DF, dye front.
phosphorylated tissue EBP50 polypeptide indicate that
the initiator methionine shown in Fig. 4 is used in vivo.
Purified recombinant EBP50 was recognized by either
of the N-ERMAD probes by blot overlay (Fig. 7 C). These
results confirmed that the human cDNA we obtained en-
codes a protein that binds with high affinity to the ezrin
and moesin N-ERMADs and is therefore almost certainly
the same cDNA that encodes the human placental candi-
date originally identified.
The ability to purify soluble EBP50 also afforded us the
opportunity to study the results of the converse blot overlay.
As shown in Fig. 7 D, when biotinylated recombinant EBP50
was used as a probe it bound to both N-ERMADs after SDS-
PAGE, demonstrating that bidirectional association between
EBP50 and the N-ERMADs is possible with this assay.
Distribution and Localization of EBP50 in Tissues and 
Cultured Cells
To explore the tissue distribution and cellular localization
of EBP50, a polyclonal antibody was raised to its COOH-
terminal 117 residues, since this region is divergent from
human TKA-1. Affinity-purified antibodies were used to
probe a blot of SDS-soluble lysates from an assortment of
murine and human tissues (Fig. 8). EBP50 was found to
varying extents in almost all the tissues examined, except
for heart and skeletal muscle. It was also found in cultured
JEG-3 human choriocarcinoma cells. In addition to the in-
formation gathered from this immunoblot, EST database
searches revealed that cDNA clones for EBP50 were also
present in breast, white blood cells, and embryo.
Figure 8. Immunoblot of EBP50 in tissues and cells. 25 mg of to-
tal proteins from murine tissues, human placenta and JEG-3 cells,
10 ng of recombinant EBP50, and 2 mg of total proteins of iso-
lated human placental microvilli were resolved on a 11.5% gel,
transferred to PVDF, and probed with affinity-purified antibody
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blast (Fig. 9 A). Double labeling with rhodamine phalloi-
din showed that EBP50 was colocalized with actin in areas
with abundant microvilli (Fig. 9, A and B, arrowheads). In
addition, the distribution of EBP50, like ezrin, was highly
polarized to the microvilli of the intestinal epithelial brush
border (Fig. 9, C and D). The specific localization of EBP50
in surface microvilli was most clearly revealed by immuno-
fluorescence microscopy of human JEG-3 cells (Fig. 10 A).
The pattern of EBP50 staining in microvilli was very simi-
lar to that seen for ezrin (Fig. 10 B).
In the human placental syncytiotrophoblast, immuno-
electron microscopy shows that EBP50, like ezrin (Berry-
man et al., 1993, 1995), specifically associates with the mi-
crovilli (Fig. 11).
EBP50 and Ezrin Associate In Vivo
To assess whether EBP50 and ezrin associate in vivo, ly-
sates of isolated human placental microvilli were subjected
The EBP50 detected on immunoblots of tissue lysates
existed as a series of multiple bands, similar to those seen
in our earlier affinity binding experiments on the N-ERMADs
(Figs. 2 and 3). This further supports the notion that the
multiple forms are the result of posttranslational phosphor-
ylation events.
EBP50 is enriched in tissues possessing extensive, polar-
ized epithelia. These include kidney, small intestine, pla-
centa, and liver (Fig. 8). Since each of these tissues con-
tains significant amounts of one or more of the ERM
family members, particularly within the abundant mi-
crovilli of their epithelia (Berryman et al., 1993; Amieva et
al., 1994), we sought to determine whether EBP50 might
also be present in these specialized cell surface structures.
Immunoblotting of proteins from isolated human placen-
tal microvilli showed that EBP50 is substantially enriched
in these structures (Fig. 8).
In cryosections of human placenta, specific EBP50 stain-
ing was seen in the apical region of the syncytiotropho-
Figure 9. Localization of
EBP50 in tissues. In human
placenta (A and B), EBP50
(A) colocalizes with actin
(stained with rhodamine
phalloidin in B) in the mi-
crovilli-rich apical regions
(arrowheads) of the syncy-
tiotrophoblast. In groups of
murine intestinal epithelial
cells (C and D), EBP50 (C) is
highly concentrated in the
microvilli of brush borders,
which are also rich in ezrin
(D). Bars: (A and B) 20 mm;
(C and D) 5 mm.Reczek et al. EBP50, an Ezrin-Radixin-Moesin–binding Protein 177
to immunoprecipitation with EBP50 and ezrin antibodies
and the immunoprecipitates examined for the presence of
ezrin and EBP50, respectively (Fig. 12). Immunoblot anal-
ysis showed that ezrin was present in the EBP50 immuno-
precipitate (Fig. 12 A, lane 3). In the converse experiment,
EBP50 was evident in the ezrin immunoprecipitate, al-
though it was difficult to discern precisely which of the
multiple species (a, b, or g) was present (Fig. 12 B, lane 3).
Neither ezrin nor EBP50 was detected in the correspond-
ing protein A control precipitates (Fig. 12 A and B, lane 2)
or preimmune serum control precipitates (not shown).
Additional support for the existence of an ezrin–EBP50
complex came from the ability to compete away the
EBP50 in ezrin immunoprecipitates by the addition of ex-
cess purified human ezrin to the reaction (Fig. 12 B, lane 4).
Discussion
We have identified a phosphoprotein, EBP50, that associ-
ates with high affinity and specificity with the N-ERMADs
of ezrin and moesin. The binding between EBP50 and the
N-ERMADs is direct: this was revealed both by blot over-
lays and by the binding between the N-ERMADs and re-
combinant EBP50. Since binding to moesin N-ERMAD
can be competed by ezrin N-ERMAD, and since the ERM
family members demonstrate high sequence identity over
this region, EBP50 probably also binds to radixin.
EBP50 is widely distributed, being particularly rich in
liver, kidney, small intestine, and placenta—tissues with
polarized epithelia and known to contain significant
amounts of ERM family members (Berryman et al., 1993;
Amieva et al., 1994). Since liver contains only trace amounts
of ezrin and moesin, but is rich in radixin, these results are
also consistent with radixin being a ligand for EBP50. Lo-
calization studies in cultured cells and tissue sections
showed a pattern of staining in cell surface microvilli indis-
tinguishable from that of ezrin. Moreover, in the placental
syncytiotrophoblast, immunoelectron microscopy reveals
that EBP50, like ezrin, is specifically associated with the
microvilli. Immunoprecipitation of EBP50 from extracts
of highly purified placental microvilli coprecipitates some
of the ezrin, and vice versa. Thus, EBP50 colocalizes with
ezrin in structures containing a supporting actin bundle,
and exists as a complex with ezrin in solubilized microvil-
lar cytoskeletons. We conclude that EBP50 is a physiologi-
cally relevant ezrin-binding protein.
The most striking feature of the 357-residue EBP50 se-
quence is the presence of two NH2-terminal, z90-residue
domains that show 74% identity to each other and homol-
ogy to PDZ domains (Fig. 6). Single or multiple PDZ do-
mains (also known as DHR domains) have been identified
in a number of cortical proteins (for review see Ponting
and Phillips, 1995; Saras and Heldin, 1996). These domains
appear to be involved in the formation of multiprotein
complexes under the plasma membrane. A well-studied
example is PSD-95, which consists of a membrane-associ-
Figure 10. Localization of EBP50 (A) and ezrin (B) in human
JEG-3 cells. The plane of focus was adjusted to the microvilli-rich
apical surface of the cells. Bar, 10 mm.
Figure 11. Immunoelectron microscopic localization of EPB50 in
human placental syncytiotrophoblast. Note the association of
EPB50 specifically with the membrane of the abundant mi-
crovilli. Bar, 0.5 mm.
Figure 12. Coimmunoprecipitation of EBP50 and ezrin from hu-
man placental microvilli. Extracts of isolated microvilli were sub-
jected to immunoprecipitation with antibodies to EBP50 (A) and
ezrin (B). Lanes 1 show a control with antibody but no extract;
lanes 2 show a control with extract but no specific antibody; and
lanes  3 show the complete reaction. The immunoprecipitates
were resolved on a 10% gel, transferred to PVDF, and then
probed with biotinylated ezrin antibody (A) or biotinylated
EBP50 antibody (B), followed by avidin-peroxidase. In B, lane 4,
excess ezrin was added to the lysate immediately before immuno-
precipitation. The migration positions of ezrin (A) and EBP50
(B) are indicated by arrows.The Journal of Cell Biology, Volume 139, 1997 178
ated guanylate kinase (MAGUK) domain fused to three
PDZ domains and an SH3 domain. This protein binds to
the COOH terminus of the Shaker-type K1 channel or to
subunits of the NMDA receptor through its PDZ domains
(Kim et al., 1995; Kornau et al., 1995). Another particu-
larly relevant example is p55 of the red blood cell, which
has a single PDZ domain and an SH3 domain followed by
a MAGUK domain. p55 binds to the COOH-terminal re-
gion of glycophorin C, perhaps through the PDZ domain,
and to the NH2-terminal domain of band 4.1 through an-
other region (Marfatia et al., 1995). Interestingly, some
protein tyrosine phosphatases within the band 4.1 super-
family, such as PTPH1 (Yang and Tonks, 1991), also con-
tain PDZ domains, suggesting that functions analogous to
those provided by ezrin/EBP50 and band 4.1/p55 are com-
bined into a single polypeptide. With this knowledge of
PDZ-containing proteins, and especially the erythrocyte
glycophorin C/p55/band 4.1 model, human EBP50 is most
likely an adaptor molecule between ezrin and an integral
membrane protein. Among the proteins that coimmuno-
precipitate with moesin from BHK cells are CD44 and a
55-kD polypeptide (Hirao et al., 1996). If this 55-kD pro-
tein is EBP50, perhaps a CD44/EBP50/moesin complex
might exist, reminiscent of the glycophorin/p55/band 4.1
complex (Marfatia et al., 1994, 1995). A different complex
must exist in ERM-rich cell types that lack CD44 (Berry-
man et al., 1995; Hirao et al., 1996).
Human EBP50 is related (84% identity) over its entire
length to rabbit NHE-RF (Weinman et al., 1995) and to
human TKA-1 over the region encompassing the two PDZ
domains (Fig. 5). Very recently it has been shown that
transfection of NHE-RF or TKA-1 (also called E3KARP)
into cultured cells confers PKA regulation on the NHE3
Na1/H1 exchanger (Yun et al., 1997). Moreover, it was
shown that a region encompassing the second PDZ do-
main of TKA-1 binds the cytoplasmic domain of NHE3, so
it is tempting to speculate that in intestine and kidney, the
only tissues that express NHE3 (Tse et al., 1992), EBP50
might provide a link between NHE3 and ERM family
members.
The identification of EBP50 as a protein that binds the
N-ERMADs of ezrin, moesin, and probably radixin raises
a number of interesting questions. The first relates to the
details of the molecular associations between EBP50 and
ERM family members. There is no obvious sequence simi-
larity between the C-ERMAD of ezrin and any region of
EBP50 that would suggest a common binding site. In fact,
there is a clear biochemical distinction between the nature
of the N-ERMAD/EBP50 and N-ERMAD/C-ERMAD
interactions. The ability of the N-ERMAD to bind to a
C-ERMAD is very sensitive to denaturation (Gary and
Bretscher, 1995), whereas the N-ERMAD is recognized
by EBP50 even after it has been denatured and subjected
to electrophoresis. Whether EBP50 and a C-ERMAD can
bind the same N-ERMAD simultaneously, or whether
they compete for binding, remains an important question.
Several observations suggest that EBP50 may be subject
to regulation. The earliest information is derived from
studies on the role of its putative homologue, rabbit pro-
tein cofactor, in the regulation of the kidney brush border
Na1/H1 exchanger (Weinman et al., 1990). Activation of
PKA by parathyroid hormone reduces the activity of the
exchanger in a reaction requiring a crude fraction contain-
ing a protein cofactor (NHE-RF). Analysis of partially pu-
rified fractions identified a polypeptide that was a sub-
strate for PKA (Morell et al., 1990; Weinman et al., 1990).
Partial sequence analysis was used to generate a peptide
antibody that recognized a 55-kD protein in kidney brush
border membranes, which appeared to be a substrate for
PKA (Weinman et al., 1993). Using the same peptide se-
quence to design an oligonucleotide probe, Weinman et al.
(1995) were able to clone a rabbit cDNA that can confer
PKA regulation of NHE3 in transfected cells (Yun et al.,
1997). Other evidence supporting the possible regulation
of EBP50 by PKA is provided by the finding that the regu-
latory subunit of PKA binds ezrin (Dransfield et al., 1997);
whether or not this interaction recruits the kinase to phos-
phorylate associated EBP50 remains to be investigated.
The presence of at least three differentially phosphory-
lated species of EBP50 in placenta is also suggestive of
regulation by phosphorylation. That these polypeptides
are modified forms of EBP50 is supported by the fact that
they have similar amino acid compositions, are recognized
by our antibody to recombinant EBP50, and bind ezrin
N-ERMAD both on the affinity column and in blot over-
lays. Thus, an attractive scenario is that phosphorylation
regulates the association between EBP50 and a membrane
protein. EBP50 has a potential PKA site (Ser338) and two
potential cdc2 sites (Ser279 and Ser301). It will be impor-
tant to identify the kinase(s) responsible for EBP50 phos-
phorylation to see in which signal transduction pathways
they lie.
In addition to the putative regulation of EBP50–mem-
brane protein association, it is also likely that the interac-
tion between EBP50 and ezrin is regulated. We have pro-
vided evidence that ezrin can exist in a dormant and
activated state, and postulated that activation induces
membrane–cytoskeletal associations (Berryman et al., 1995).
A possible scenario is that dormant ezrin and EBP50 do
not associate, but upon activation a cascade of protein in-
teractions occurs driving the membrane protein/EBP50/
ezrin/F-actin linkage. What membrane proteins might be
bound, or how the associations are regulated, both at the
level of EBP50 and in terms of the regulation of ERM pro-
teins through conformational changes, are questions for
future studies.
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Note Added in Proof. Reinspection of the TKA-1 cDNA sequence, to-
gether with the newly deposited sequence for human E3KARP (these se-
quence data are available from EMBL/GenBank/DDBJ under accession
number AF004900), suggests an error in the TKA-1 cDNA sequence that
changes the reading frame at residue 310. In the new frame, TKA-1/
E3KARP has 337 residues and shows 55% indentity to EBP50 throughout
the protein.
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